Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001662252-17-000254
Filing Date
2017-12-29
Accepted
2017-12-29 16:31:48
Documents
55
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rcha10q093017.htm 10-Q 476067
2 EX-31.1 ex31_1.htm EX-31.1 8618
3 EX-31.2 ex31_2.htm EX-31.2 8660
4 EX-32.1 ex32_1.htm EX-32.1 3635
  Complete submission text file 0001662252-17-000254.txt   3727439

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE rcha-20170930.xml EX-101.INS 612642
6 XBRL SCHEMA FILE rcha-20170930.xsd EX-101.SCH 59150
7 XBRL CALCULATION FILE rcha-20170930_cal.xml EX-101.CAL 34451
8 XBRL DEFINITION FILE rcha-20170930_def.xml EX-101.DEF 158904
9 XBRL LABEL FILE rcha-20170930_lab.xml EX-101.LAB 252558
10 XBRL PRESENTATION FILE rcha-20170930_pre.xml EX-101.PRE 243522
Mailing Address 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS CA 90212
Business Address 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS CA 90212 (424) 230-7001
Rich Pharmaceuticals, Inc. (Filer) CIK: 0001504389 (see all company filings)

EIN.: 463259117 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54767 | Film No.: 171282273
SIC: 2834 Pharmaceutical Preparations